Safety Profile of Idelalisib in Patients With Refractory Follicular Lymphoma
NCT03568929
·
clinicaltrials.gov ↗
COMPLETED
Status
257
Enrollment
INDUSTRY
Sponsor class
Conditions
Follicular Non-Hodgkin's Lymphoma Refractory
Interventions
DRUG:
Idelalisib
Sponsor
Gilead Sciences